Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Disseminated intravascular prothrombin complex

The risk of disseminated intravascular coagulation and other thrombotic events appears to be less with factor VII than with activated prothrombin complex products (1,18). However, disseminated intravascular coagulation after infusion of recombinant factor Vila has been reported (19,20). [Pg.1318]

This may explain the effectiveness of treating patients with hemophilia who have inhibitors with high doses of factor VIII. Another approach involves the use of prothrombin complex concentrate to treat bleeding episodes in patients with factor VIII inhibitors (38) however, thromboembolic complications related to higher doses of prothrombin complex concentrate have been described, although these are relatively rare (39,40). Thrombotic events are extremely rare when highly purified factor IX is used. Activated prothrombin complex concentrate is also effective in patients with factor VIII inhibitors (41). Serious complications are rare, but disseminated intravascular coagulation has been reported (42). [Pg.1321]

The administration of prothrombin complex concentrate to reverse anticoagulant treatment has been associated with thrombotic complications, such as disseminated intravascular coagulation (8). However, such complications have typically occurred in patients with liver failure or after repeated treatment, such as in patients with hemophilia B treated with prothrombin complex concentrate (9). [Pg.2971]

Relative contraindications for prothrombin complex concentrate are liver disease, coronary heart disease, and factors that predispose to thrombosis (11). It is contraindicated in disseminated intravascular coagulopathy and hyperfibrinolysis. [Pg.2972]

Rodie PH, Stirling C, Mayne EE, Ludlam CA. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost 1999 81(4) 667. [Pg.2972]

Cardiovascular The main adverse effect of prothrombin complex concentrates is a risk of thrombosis, as patients taking oral anticoagulants have prothrombotic susceptibility factors [31, 33 ]. Reported thromboembolic complications include ischemic stroke, venous thromboembolism (venous thrombosis or pulmonary embolism), myocardial infarction, and disseminated intravascular coagulation [32 ]. [Pg.519]

Hematologic Historically, there was concern that prothrombin complex concentrates were associated with thrombotic events such as stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, and disseminated intravascular coagulation. These events resulted mainly from the use of prothrombin complex concentrates as source of factor IX in patients with hemophilia B, and in particular after surgery, but the reported incidence is low and there is considerable evidence that the risk of thrombosis has been minimized with current prothrombin complex concentrates by reduced use of activated factors and the... [Pg.680]


See other pages where Disseminated intravascular prothrombin complex is mentioned: [Pg.162]    [Pg.696]   


SEARCH



Disseminated

Disseminated intravascular

Dissemination

Intravascular

Prothrombin

Prothrombin complex

© 2024 chempedia.info